MedPath

Diphenhydramine

Generic Name
Diphenhydramine
Brand Names
Acetadryl, Advil PM, Aleve PM, Allegra Cooling Relief Anti-itch, Banophen, Benadryl, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Calagel, Damylin With Codeine, Dimetapp Nighttime Cold & Congestion, Diphen, Diphenhist, Diphenist, Excedrin PM Triple Action, Goody's PM, Legatrin PM, Motrin PM, Nytol, Nytol Quickgels, Percogesic Reformulated Jan 2011, Siladryl, Simply Sleep, Sleepinal, Sominex, Triaminic Night Time Cold & Cough, Tylenol PM, Unisom, Unisom Sleep, Vanamine, Wal-dryl, Wal-som (doxylamine), Zzzquil
Drug Type
Small Molecule
Chemical Formula
C17H21NO
CAS Number
58-73-1
Unique Ingredient Identifier
8GTS82S83M
Background

Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes . However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties . As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system . While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use .

Diphenhydramine is also used in combination with 8-chlorotheophylline as the anti-nausea drug Dimenhydrinate where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system .

Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.

Indication

Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea .

Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:

i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated ;

ii) the active treatment of motion sickness ; and

iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents .

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Allergic cough, Allergy to Tree Pollen, Anaphylaxis, Angioedema, Common Cold, Conjunctival irritation, Cough, Cough Variant Asthma, Cough caused by Common Cold, Eye allergy, Fever, Insect Bites, Insect Stings, Insomnia, Irritative cough, Itching of the nose, Itching of the throat, Motion Sickness, Nasal Congestion, Oral Mucositis, Pain, Parkinsonian Syndromes, Productive cough, Pruritus, Rash, Rhinorrhoea, Sinus Congestion, Sinus headache, Skin Irritation, Sneezing, Sunburn, Symptoms of Acute Bronchitis Accompanied by Coughing, Upper respiratory tract hypersensitivity reaction, site unspecified, Urticaria, Cold or flu syndrome, Dermatographism, Dry cough, Watery itchy eyes
Associated Therapies
Airway secretion clearance therapy, Expectorant

Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls

Not Applicable
Suspended
Conditions
Bulimia Nervosa
Eating Disorders
Reward
Catechol-O-methyltransferase
Dopamine
Interventions
Drug: AMPT/ Demser
Drug: Diphenhydramine
Drug: Placebo
First Posted Date
2014-07-02
Last Posted Date
2019-01-24
Lead Sponsor
University of Bern
Target Recruit Count
60
Registration Number
NCT02179814
Locations
🇨🇭

University Hospital of Psychiatry, University of Bern, Bern 60, Switzerland

Histamine Glutamate Antagonism in Stroke

Phase 2
Completed
Conditions
Acute Cerebrovascular Accident
Cerebral Edema
Interventions
First Posted Date
2014-05-20
Last Posted Date
2015-12-15
Lead Sponsor
University of Florida
Target Recruit Count
3
Registration Number
NCT02142712
Locations
🇺🇸

Shands Hospital at University of Florida, Gainesville, Florida, United States

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

Phase 2
Completed
Conditions
Depression
Interventions
First Posted Date
2014-04-08
Last Posted Date
2018-09-14
Lead Sponsor
NYU Langone Health
Target Recruit Count
21
Registration Number
NCT02106325
Locations
🇺🇸

Bellevue Hospital Center, New York, New York, United States

🇺🇸

NYU Langone Medical Center/Tisch Hospital, New York, New York, United States

Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial

Phase 4
Completed
Conditions
Migraine Headaches
Nausea
Restlessness
Interventions
First Posted Date
2014-03-28
Last Posted Date
2014-03-28
Lead Sponsor
United States Naval Medical Center, Portsmouth
Target Recruit Count
68
Registration Number
NCT02098499
Locations
🇺🇸

Naval Medical Center Portsmouth, Portsmouth, Virginia, United States

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Phase 2
Completed
Conditions
Alcohol Dependence
Interventions
Drug: Diphenhydramine
Drug: Psilocybin
Behavioral: Motivational Enhancement and Taking Action (META)
First Posted Date
2014-02-12
Last Posted Date
2022-11-08
Lead Sponsor
NYU Langone Health
Target Recruit Count
95
Registration Number
NCT02061293
Locations
🇺🇸

Clinical and Translational Science Institute, NYU Langone Medical Center, New York, New York, United States

🇺🇸

University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States

Psilocybin-facilitated Treatment for Cocaine Use

Phase 2
Completed
Conditions
Cocaine-Related Disorders
Interventions
First Posted Date
2014-01-15
Last Posted Date
2024-10-24
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
40
Registration Number
NCT02037126
Locations
🇺🇸

UAB Outpatient Clinical Research Unit, Birmingham, Alabama, United States

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Phase 2
Terminated
Conditions
Kidney Transplantation
Interventions
First Posted Date
2014-01-08
Last Posted Date
2018-09-24
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
4
Registration Number
NCT02029638
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

Phase 3
Completed
Conditions
Acute Urticaria
Interventions
Drug: JDP-205 Injection
Drug: Diphenhydramine
First Posted Date
2013-12-30
Last Posted Date
2024-02-09
Lead Sponsor
JDP Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT02023164
Locations
🇨🇦

Del Carpio Independent Practice, Montréal, Quebec, Canada

🇨🇦

Glengarry Memorial Hospital, Independent Practice, Alexandria, Ontario, Canada

🇺🇸

OSU Hospitals, Department of Emergency Medicine, Columbus, Ohio, United States

and more 3 locations

Anti-histamines and Methacholine Challenges.

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2013-11-15
Last Posted Date
2015-04-08
Lead Sponsor
Don Cockcroft
Target Recruit Count
12
Registration Number
NCT01985789
Locations
🇨🇦

University of Saskatchewan, Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath